MedTrace Logo

Hyperkalaemia and Its Impact on Therapy with RAASi

NCT04249648 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 651

Last updated 2024-11-14

No results posted yet for this study

Summary

Renin-angiotensin-aldosterone system inhibitors (RAASi) have transformed prognosis of patients with heart failure with reduced ejection fraction, diabetic nephropathy and chronic kidney disease. However, in everyday clinical practice patients often receive suboptimal doses of RAASi. The development of hyperkalaemia is one of the reasons for dose reduction or complete withdrawal of RAASi and this in turn is likely to have an adverse impact on patient outcomes. Yet it remains unknown precisely how often hyperkalaemia leads to changes to RAASi doses, if it is the sole reason, or whether this occurs in combination with other clinical situations such as worsened renal function and hypotension. It is also unclear what influences the decision-making process of healthcare professionals in managing patients with hyperkalaemia who take RAASi and if this is influenced by specialty, experience or indications for RAASi.

In order to improve our understanding of the problem we are taking forward a research study (made up of 3 complimentary studies). These data are needed to help achieve our ultimate goal of improving the care of patients with prognostic indication for RAASi.

Conditions

  • Hyperkalaemia
  • Heart Failure with Reduced Ejection Fraction
  • Left Ventricular Systolic Dysfunction

Sponsors & Collaborators

  • Vifor Pharma

    collaborator INDUSTRY

  • Portsmouth Hospitals NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Paul R Kalra, Professor · Queen Alexandra Hospital, Portsmouth, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249648 on ClinicalTrials.gov